We serve 6-Quinolinecarboxylic acid, 4-chloro-7-methoxy-, methyl ester CAS:205448-66-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Contact us for information like 6-Quinolinecarboxylic acid, 4-chloro-7-methoxy-, methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 4-chloro-7-methoxyquinoline-6-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Quinolinecarboxylic acid,4-chloro-7-methoxy-,methyl ester Use and application,6-Quinolinecarboxylic acid,4-chloro-7-methoxy-,methyl ester technical grade,usp/ep/jp grade.
Related News: Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.S-(+)-N,N-Dimethyl-3-(1-naphthoxy)-3-(2-thienyl)-1-propylamine oxalate manufacturer Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.N-Phenyltrifluoromethanesulfonimide supplier The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself.(R)-(-)-Glycidyl phthalimide vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).
